Regulatory
Screened through a
he future of clinical trials, we’ve often been told, is digital. As far back as 2012, a number of major pharmaceutical companies partnered to establish a group to investigate the potential of new technology, while giants like Pfizer launched web-based trial outreach platforms. Over the last decade the star of digital trials has risen further
T 8
Once enough support builds to integrate a new technology to support clinical trials, the FDA screen
responds. That’s exactly what happened early this year – with a new document on the use of digital health technologies (DHTs) and remote data acquisition making waves across the industry. Andrea Valentino speaks to Jennifer Goldsack at the Digital Medicine Society, and Lindsay Kehoe at the Clinical Trials Transformation Initiative, to understand what the guidance says, how it speaks to the wide prevalence of digital trials across the sector and how trial conveners will have to tackle cybersecurity and data analysis challenges if they want this emerging fi eld to grow even further.
still. According to work by Grand View Research, the global virtual clinical trials market was already worth $7.8bn in 2021, with the industry expected to enjoy CAGR of 5.7% through the end of the decade. Nor is this explosion particularly hard to understand. From better technology to algorithms that become more robust each day, both prodded
Clinical Trials Insight /
www.worldpharmaceuticals.net
Macrovector/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
